Geriatrics

Patients treated with faricimab every 16 weeks had a mean improvement of 11.4 letters from baseline, compared to 9.6 letters in those treated with ranibizumab every 4 weeks.

The phase 2 FILLY trial found that APL-2 injections both monthly and every other month slowed lesion growth compared to sham.

R. Theodore Smith MD, PhD, discusses the concept of hyperspectral autofluorescence imaging and how clinicians can learn more from this method than standard autofluorescence imaging.

According to an analysis of 84,228 online reviews of 7,372 ophthalmologists, the average rating for a physician with a wait time exceeding 15 minutes was 3.903.

In a new study conducted in Taiwan, investigators found that use of metformin to treat diabetes also reduced the risk of AMD development over a 13-year period.

Peter Campochiaro, MD, professor of ophthalmology and director of the retinal cell and molecular laboratory at Johns Hopkins explains the burdens of receiving frequent anti-VEGF injection treatments.

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months was 1.3 in a phase 1 cohort study.

R. Theodore Smith MD, PhD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai discusses new research to reduce the burden of AMD and how imaging can revolutionize the retina space.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

A comparison of patients in a pair of European-based studies tracking adherence to the diet found those eating healthier were significantly less likely to develop late-stage AMD.

Zinc is the second most abundant trace element in the human body after iron, and is present in high concentration in the human eye.

There is a found significant unmet need to develop treatments that limit or protect against scar formation, GA development, retinal thinning, fluid increase, and lesions, as an accompaniment to anti-VEGF therapy.

The findings lend to investigators believe that earlier endpoints for AMD diagnosis are needed.

In animal models, not only did the drug help protect apelin function-deficient models from laser-induced choroidal neovascularization, but it did it through unique mechanisms that were independent of VEGF function.

The Novartis humanized single-chain antibody fragment previously showed improved best corrected visual acuity in patients with nAMD versus aflibercept.

Computers can do as well as clinicians in diagnosing age-related macular degeneration, say investigators who have developed tools based on artificial intelligence to detect the disorder.

Investigators reported an overall mean estimation error ranging from 3.47% to 5.29% in five-year outcomes for patients with AMD.

The acceptance comes less than a month since the FDA had approved the anti-VEGF therapy for the treatment of wet AMD. Its mechanism of action allows it to block new blood vessel growth and the passing of fluids through blood vessels in the eye.

A recent study found the costs of medical, laser, and surgical interventions were 2.5% or more of the median annual household income for many patients worldwide.

Among patients who were lost to follow-up over a year, just 7.4% attended a follow-up visit after the observed 12 months. In the total loss to follow-up patient population, they reported a mean 7.8 injection treatments and 8.5 clinic visits. In patients not lost, they reported a mean 14.3 injections and 17.1 visits.

The COMPASS-XT five-year analysis reported that patients treated with the micro-stent experienced statistically significant loss of endothelial cells compared to the patients treated with lone cataract surgery.

A modified 12-week dosing schedule is now available for physicians administering the vascular endothelial growth factor (VEGF) inhibitor to patients with wet age-related macular degeneration.

The results of a new study point to age-related macular degeneration, diabetic retinopathy, and glaucoma as potential early warning signs that an individual is at risk for developing Alzheimer disease or dementia.

In an effort to reprogram retina cell regeneration, investigators activated dormant stem cells then aided other stem cells in developing into rod photoreceptor cells—the most abundant cell type in the retina which first aid the retina in sensing light.